¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Trans Br Soc Study Orthod"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • family study
    °¡Á·Á¶»ç
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • intervening study
    °³ÀÔ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°Çа˻ç
  • migrant study
    ÀÌÁֹבּ¸
  • mixing study
    È¥ÇÕ°Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • nonconcurrent study
    ºñµ¿½ÃÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ½ÇÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • nested case control study
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • retrospective study
    ÈÄÇâÀû¿¬±¸
  • single blind study
    ´ÜÀÏ<¼ø>¸Í°Ë¹ý.
  • time study
    ½Ã°£¿¬±¸(¡­æÚϼ).
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NCS National Collaborative Study; neocarcinostatin; nerve conduction study; newborn calf serum; no conce...
OTC Ornithine Trans-Carbamylase
PTHC Percutaneous Trans-Hepatic Cholangiography(-gram)
  = PTC
TAE Trans-Arterial(-Catheter) Embolization
  Angiography¿Í µ¿½Ã¿¡ Gel Form°ú CTx AgentÀÇ Mixed m...
TBLB Trans-Bronchial Lung Biopsy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SOC sham-operated control
SOC store operated channels
Study 1 study
Study 2 study
Study A study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
  • neurophysiological study
    ½Å°æ »ý¸®ÇÐÀû ¿¬±¸
  • phase 1 study
    ÀÓ»ó Á¦1»ó ½ÃÇè
  • prospective study
    ÀüÇâÀû ¿¬±¸, ÃßÀû ¿¬±¸
  • psychophysical study
    Á¤½Å ½ÅüÇÐ ¿¬±¸
  • psychophysiological study
    Á¤½Å »ý¸®ÇÐÀû ¿¬±¸
  • radionuclei study
    ÇÙ ¹æ»ç¼± ÃÔ¿µ
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • secretory study
    ºÐºñ °Ë»ç
  • study cast
    ¿¬±¸¿ë ¸ðÇü, Áø´Ü ¸ðÇü
    µ¿ÀǾî=diagnostic cast.
  • video-urodynamic study
    ºñµð¿À ¿ä¿ªÇÐ °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
trans Golgi network <cell biology> A complex of membranous tubules and vesicles, near the trans face of the Golgi, which is thought to be a major intersection for intracellular traffic of vesicles.
(18 Nov 1997)
trans-Golgi reticulum That part of the Golgi apparatus that takes newly processed proteins and delivers them to secretory vesicles that will fuse with other biomembranes (e.g., the plasma membrane).
(05 Mar 2000)
trans-octaprenyltranstransferase <enzyme> Level of isopentenyl diphosphate-magnesium(ipp-mg) is decisive in affecting the chain length of the products of prenyltransferase reaction
Registry number: EC 2.5.1.11
Synonym: solanesyl diphosphate synthase, solanesyl pyrophosphate synthetase
(26 Jun 1999)
trans-pentaprenyltranstransferase <enzyme> From micrococcus luteus b-p26; composed of 2 components; requires all-trans farnesyl or all-trans-geranylgeranyl pyrophosphate
Registry number: EC 2.5.1.33
Synonym: all-trans-hexaprenylpyrophosphate synthase, hexaprenyldiphosphate synthetase, trans-pentaprenyltransferase, hexaprenylpyrophosphate synthetase
(26 Jun 1999)
trans-retinal The orange retinaldehyde resulting from the action of light on the rhodopsin of the retina, which converts the 11-cis-retinal component of the rhodopsin to all-trans-retinal plus opsin.
Synonym: trans-retinal, visual yellow.
(05 Mar 2000)
trans splicing <molecular biology> Relating to RNA splicing of two different pre mRNA molecules together. Seems to rely on intron like sequences.
Contrasts with the normal cis splicing of conventional RNA molecules.
(19 Jan 1998)
trans-splicing Formation of spliced products containing portions of two different transcripts.
(05 Mar 2000)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á